JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.
Life Sciences partner Stephen Paul Mahinka comments on the FTC v. Cephalon, the FTC's challenge on pay-for-delay agreements restricting generic drug market entry.